Safety of the COVID‐19 vaccine booster in patients with immunobullous diseases: A cross‐sectional study of the International Pemphigus and Pemphigoid Foundation

COVID-19 and autoimmune bullous diseases: Lessons learned

“…Other side-effects of the primary COVID-19 vaccination series included muscle aches (32.8%), injection site reaction (pain, itching and/or redness) (28.8%), sleepiness (26.9%), headache (25%), chills (23.1%), weakness (22.5%), fever (20%), nausea (10%), and vomiting (2%) [ 24 ]. Our follow-up study showed that COVID-19 booster vaccines may not be associated with an increased risk of adverse events, including possible AIBD flare/worsening, when compared with the prior vaccination [ 25 ].…”

De novo pemphigus vulgaris and pemphigus foliaceus development following COVID‐19 infection and vaccination: Matched case–control study

“…Episodes of PV/PF exacerbation following COVID-19 infection/vaccination are reported in literature (see, for example, 8,9 ). However, exacerbations could be subjectively reported by patients and clinicians, thus introducing an important diagnostic bias.…”